Latest Grifols S.A. Stories

2014-04-17 08:28:45

- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries BARCELONA, Spain, April 17, 2014 /PRNewswire/ -- Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) today announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a...

2014-04-04 12:27:38

BARCELONA, Spain, April 4, 2014 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), announced that it has filed its 2013 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 4, 2014. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2013. Form 20-F can be accessed electronically through the Grifols website at...

2013-09-26 23:02:12

Reportbuyer.com just published a new market research report: Global Intravenous Immunoglobulin (IVIg) Industry. London (PRWEB) September 26, 2013 This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these...

2011-06-03 12:56:00

BARCELONA, Spain, June 3, 2011 /PRNewswire/ -- Grifols, S.A. (NASDAQ: GRFS) ("Grifols") a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that on June 1, 2011, Grifols completed its acquisition of Talecris Biotherapeutics Holdings Corp. ("Talecris"). In partial consideration for their shares, Talecris shareholders received Grifols non-voting shares that trade in the U.S. as Grifols ADSs. These new Grifols ADSs are listed on the...

2011-06-01 05:30:00

RESEARCH TRIANGLE PARK, N.C., June 1, 2011 /PRNewswire/ -- Grifols, S.A. (GRF.MC) and Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) announced today that the U.S. Federal Trade Commission (FTC) has accepted for public comment a Consent Agreement that outlines the conditions necessary for Grifols' acquisition of Talecris to proceed. Grifols may close the transaction without further action by the FTC, and closing is expected to occur June 1, 2011, or shortly thereafter. The terms of...

Word of the Day
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'